Zobrazeno 1 - 10
of 968
pro vyhledávání: ''
Autor:
Emanuela Ercolano, Bora Agit, Emmanuel Atangana Maze, David A Hilton, Sylwia Ammoun, Shona Reeves, Robert D Belshaw, Kathreena M Kurian, C. Oliver Hanemann, David Parkinson, Liyam Laraba
Publikováno v:
Cancer Research. 82:235-247
Deficiency of the tumor suppressor Merlin causes development of schwannoma, meningioma, and ependymoma tumors, which can occur spontaneously or in the hereditary disease neurofibromatosis type 2 (NF2). Merlin mutations are also relevant in a variety
Publikováno v:
Molecular Cancer Research. 20:3-10
Centromere dysfunctions leading to numerical chromosome alterations are believed to be closely related to human cancers. As a centromere-specific protein, centromere protein A (CENP-A) replaces the histone H3 in centromeres and is therefore considere
Autor:
Aakash Desai, Vivek Subbiah, Jason Roszik, Jacob J. Adashek, Gilbert J. Cote, Alexander Y. Andreev-Drakhlin
Publikováno v:
Mol Cancer Ther
Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the t
Publikováno v:
Cancer Discov
Knowledge of the human microbiome, which is likely a critical factor in the initiation, progression, and prognosis of multiple forms of cancer, is rapidly expanding. In this review, we focus on recent investigations to discern putative, causative mic
Autor:
Daqian Zhan, Alan K. Meeker, Hernando Lopez-Bertoni, Charles G. Eberhart, Yi Fu, Ding Ma, Yunqing Li, Bachchu Lal, John Laterra, Shuli Xia, Mingyao Ying, Shuang Wei
Publikováno v:
Mol Cancer Res
Heterozygous isocitrate dehydrogenase (IDH) R132H mutation (IDH1R132H/WT) is an early event during gliomagenesis. Clinically, patients with glioma carrying mutant IDH1 respond better to antitumor therapies. However, the mechanism by which IDH1 mutati
Autor:
Melanie S. Flint, Marta Falcinelli, Susan K. Lutgendorf, Suzanne D. Conzen, Premal H. Thaker, Renée L. Flaherty
Publikováno v:
Cancer Res
The hypothesis that the physiologic response to psychologic stress influences the initiation of cancer is highly controversial. The link between initiating stressors, the psychologic stress response, and disease is plausible, considering that the str
Autor:
Viswanathan Muthusamy, Brandon M. Gassaway, Jesse Rinehart, David L. Rimm, Maria Apostolidi, Ioannis A. Vathiotis, Patricia Gaule
Publikováno v:
Cancer Res
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low survival rate and a lack of biomarkers and targeted treatments. Here, we target pyruvate kinase M2 (PKM2), a key metabolic component of oncogenesis. In patient
Autor:
Jeffrey A. Meyerhardt, Edward Giovannucci, Koichiro Haruki, Mingyang Song, Eliezer M. Van Allen, Kana Wu, Marios Giannakis, Shuji Ogino, Andrew D. Cherniack, Jonathan A. Nowak, Brendan Reardon, Rong Zhong, Charles S. Fuchs, Henry Lee-Six, Carino Gurjao, Liam F. Spurr, Xuehong Zhang, Yvonne Y. Li, Tomotaka Ugai
Publikováno v:
Cancer Discov
Several risk factors have been established for colorectal cancer, yet their direct mutagenic effects in patients' tumors remain to be elucidated. Here, we leveraged whole-exome sequencing data from 900 colorectal cancer cases that had occurred in thr
Publikováno v:
Cancer Research. 81:4174-4182
Despite extensive progress in developing anticancer therapies, therapy resistance remains a major challenge that promotes disease relapse. The changes that lead to therapy resistance can be intrinsically present or may be initiated during treatment.
Autor:
Terence M. Williams, Shengyan Xiang, Francisca Beato, Hua Yang, Jose G. Trevino, Jason B. Fleming, Bin Fang, Said M. Sebti, Kazim Husain, Aslamuzzaman Kazi, Mokenge P. Malafa, Liwei Chen, rajanikanth vangipurapu, John M. Koomen, Eric A. Welsh, Patrick W. Underwood
Publikováno v:
Clin Cancer Res
Purpose: Among human cancers that harbor mutant (mt) KRas, some, but not all, are dependent on mt KRas. However, little is known about what drives KRas dependency. Experimental Design: Global phosphoproteomics, screening of a chemical library of FDA